As clinicians have increasing amount of checkpoint inhibitors to select from in the treatment of advanced stage NSCLC patients, it will be important to understand potential differences in efficacy and toxicity profiles of these agents

As clinicians have increasing amount of checkpoint inhibitors to select from in the treatment of advanced stage NSCLC patients, it will be important to understand potential differences in efficacy and toxicity profiles of these agents. in response rate between PD-1 (19%) and PD-L1 (18.6%) inhibitors, p=0.17. The incidence of overall adverse events (AEs) was comparable…